Given the increase in immunoproteasome activity and dependency in AML and the resulting broader degradation of critical proteins, our data suggest that coactivation of UBE2N is required in these leukemias to regulate proteostasis of oncogenic pathways by stabilizing critical proteins. Here, UBE2N is linked to acute myeloid leukemia.